Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Biomarkers and insulin sensitivity in women with polycystic ovary syndrome: characteristics and predictive capacity.
Author: Cassar, S.
Teede, H.
Harrison, C.
Joham, A.
Moran, L.
Stepto, N.
Citation: Clinical Endocrinology, 2015; 83(1):50-58
Publisher: Wiley
Issue Date: 2015
ISSN: 0300-0664
Statement of
Samantha Cassar, Helena J. Teede, Cheryce L. Harrison, Anju E. Joham, Lisa J. Moran, and Nigel K. Stepto
Abstract: Objective: Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with metabolic complications. Metabolic biomarkers with roles in obesity, glycaemic control and lipid metabolism are potentially relevant in PCOS. The aim was to investigate metabolic biomarkers in lean and overweight women with and without PCOS and to determine whether any biomarker was able to predict insulin resistance in PCOS. Design: Cross-sectional study. Patients: Eighty-four women (22 overweight and 22 lean women with PCOS, 18 overweight and 22 lean women without PCOS) were recruited from the community and categorized based on PCOS and BMI status. Measurements Primary outcomes were metabolic biomarkers [ghrelin, resistin, visfatin, glucagon-like peptide-1 (GLP-1), leptin, plasminogen activator inhibitor -1 (PAI-1), glucose-dependent insulinotropic polypeptide (GIP) and C-Peptide] measured using the Bio-Plex Pro Diabetes assay and insulin sensitivity as assessed by glucose infusion rate on euglycaemic-hyperinsulinaemic clamp. Results: The biomarkers C-peptide, leptin, ghrelin and visfatin were different between overweight and lean women, irrespective of PCOS status. The concentration of circulating biomarkers did not differ between women with PCOS diagnosed by the Rotterdam criteria or National Institute of Health criteria. PAI-1 was the only biomarker that significantly predicted insulin resistance in both control women (P = 0.04) and women with PCOS (P = 0.01). Conclusions Biomarkers associated with metabolic diseases appear more strongly associated with obesity rather than PCOS status. PAI-1 may also be a novel independent biomarker and predictor of insulin resistance in women with and without PCOS.
Keywords: Humans
Polycystic Ovary Syndrome
Insulin Resistance
Gastric Inhibitory Polypeptide
Plasminogen Activator Inhibitor 1
Glucose Clamp Technique
Case-Control Studies
Cross-Sectional Studies
Predictive Value of Tests
Glucagon-Like Peptide 1
Nicotinamide Phosphoribosyltransferase
Young Adult
Rights: © 2014 John Wiley & Sons Ltd
DOI: 10.1111/cen.12619
Grant ID:
Published version:
Appears in Collections:Aurora harvest 2
Obstetrics and Gynaecology publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.